| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Stonepine Capital Management, LLC | 11% | +7% | $47,201,973 | +$3,465,711 | 3,271,100 | +7.9% | Stonepine Capital Management, LLC | 29 Jan 2026 |
| INTEGRATED CORE STRATEGIES (US) LLC | 9% | $13,673,537 | 1,901,585 | Integrated Core Strategies (US) LLC | 20 Oct 2025 | |||
| ARMISTICE CAPITAL, LLC | 5% | $7,049,313 | 1,081,183 | Armistice Capital, LLC | 31 Mar 2025 | |||
| Ikarian Capital, LLC | 13% | -50% | $3,052,472 | 211,538 | 0% | Ikarian Capital, LLC | 31 Jan 2026 | |
| Aberdeen Group plc | 8.9% | $1,082,250 | 75,000 | Aberdeen Group plc | 31 Dec 2025 | |||
| Resolute Capital Asset Partners LLC | 8.5% | $671,000 | 50,000 | Resolute Capital Asset Partners LLC | 10 Oct 2025 |
As of 30 Sep 2025, 4 institutional investors reported holding 1,491 shares of Quoin Pharmaceuticals, Ltd. - American Depositary Shares, each representing thirty-five (35) Ordinary Shares, no par value per share (QNRX). This represents 0.09% of the company’s total 1,678,873 outstanding shares.